Inhibiting melanin production to reduce the appearance of new pigmentation
Clinical criteria require a documented diagnosis of obesity (BMI 95th percentile for age and sex, or BMI 30 kg/m at age 17+) plus at least one weight-related comorbidity, such as type 2 diabetes, prediabetes, hypertension, or dyslipidemia
doi: 10.1177/0333102417702132 11
By addressing these underlying hormonal disruptions, MHT helps create the conditions your body needs to respond more effectively to movement, nutrition, and, when needed, additional treatments like GLP-1 medications
As obesity treatment evolves with new pharmacological options, the ability to facilitate meaningful behavior change conversations remains critical